Results 141 to 150 of about 27,683 (265)

Pleuritis Induced by Brigatinib During the Treatment of Non‐Small Cell Lung Cancer

open access: yesRespirology Case Reports, Volume 14, Issue 5, May 2026.
This is the first reported case of brigatinib‐induced pleuritis in ALK‐positive lung cancer. Pleural effusion resolved after discontinuation and did not recur at a reduced dose of 30 mg/day. Dose reduction to 30 mg/day could be a safe and effective management strategy in selected patients.
Shohei Yano   +7 more
wiley   +1 more source

Case Reports : Rheumatoid pleural effusions and trapped lung : An uncommon complication of rheumatoid arthritis [PDF]

open access: yes, 2015
Rheumatoid arthritis (RA) is a disease affecting approximately 1[percent] of the population. It is familiarly defined as "chronic, symmetric, debilitating and destructive inflammatory polyarthritis characterized by proliferative synovial tissue (pannus ...
Clary, Kevin   +4 more
core  

Primary Hepatoid Adenocarcinoma of the Lung With Signet Ring Cell Differentiation and Widespread Osseous Metastases: A Case Report

open access: yesRespirology Case Reports, Volume 14, Issue 5, May 2026.
We present a case of hepatoid adenocarcinoma in the lung which was initially misdiagnosed as pneumonia and rapidly progressed to widespread metastatic disease. This case emphasises the diagnostic difficulty, radiological and histopathologic characteristics, and aggressive clinical behaviour of this rare tumour and underscores the need for early ...
Rami Khader   +7 more
wiley   +1 more source

Paradoxical Pyogenic Granuloma Associated With Ramucirumab but Not Bevacizumab: A Case Suggesting Differential Effects of VEGF Receptor and Ligand Inhibition

open access: yesRespirology Case Reports, Volume 14, Issue 5, May 2026.
We report a case of multifocal pyogenic granuloma that developed during ramucirumab therapy but did not recur after switching to bevacizumab. ABSTRACT Pyogenic granuloma is a benign vascular lesion that may bleed repeatedly and impair daily activities.
Akina Nigi   +3 more
wiley   +1 more source

Recurrent Pneumothorax With Bronchopleural Fistula in Primary Multidrug‐Resistant Pulmonary Tuberculosis: A Challenging Case

open access: yesRespirology Case Reports, Volume 14, Issue 5, May 2026.
A 41‐year‐old man with primary multidrug‐resistant pulmonary tuberculosis (MDR‐TB) developed recurrent pneumothorax and a bronchopleural fistula (BPF). Despite persistent air leak (PAL) after initial video‐assisted thoracoscopic surgery (VATS), definitive open thoracotomy with decortication and fistula repair led to sustained lung re‐expansion.
Primawati   +2 more
wiley   +1 more source

Diagnostic and prognostic utility of pleural fluid neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratios in exudative pleural effusion

open access: yesThe Egyptian Journal of Bronchology
Background Exudative pleural effusion (EPE) remains a diagnostic and therapeutic challenge. Inflammatory biomarkers, such as the neutrophil-to-lymphocyte ratio (NLR) and monocyte-to-lymphocyte ratio (MLR), have been proposed as non-invasive, cost ...
Mohamed Sabry Eltarhony
doaj   +1 more source

Demystifying molecular techniques in cytopathology practice [PDF]

open access: yes, 2008
The last decade was stimulating with the introduction of new molecular techniques to be applied in pathology laboratories. Accordingly, cytology was also benefited with the innovations emerged from this new era.
Longatto Filho, Adhemar   +3 more
core  

A Case of Anti‐AMY1‐Positive Lung Squamous Cell Carcinoma With Severe Hyperamylasemia Linked to Disease Progression

open access: yesRespirology Case Reports, Volume 14, Issue 5, May 2026.
We present a case of anti‐AMY1‐positive lung squamous cell carcinoma (LUSC) with severe hyperamylasemia. To our knowledge, no previous cases of LUSC have been reported with both histological evidence of amylase production and hyperamylasemia. This case provides new evidence that LUSC can produce amylase and cause hyperamylasemia. ABSTRACT A 74‐year‐old
Yusuke Nakamura   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy